Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 304Stomach Neoplasms 34Neoplasm Metastasis 24Neoplasms 16Colorectal Neoplasms 16Breast Neoplasms, Male 16HER2-positive Breast Cancer 11Inflammatory Breast Neoplasms 10Triple Negative Breast Neoplasms 9Esophageal Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Rectal Neoplasms 7Adenocarcinoma 7Colonic Neoplasms 6Urinary Bladder Neoplasms 5Pathologic Complete Response 5Biliary Tract Neoplasms 5Urologic Neoplasms 4Salivary Gland Neoplasms 4Prostatic Neoplasms 4Lung Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ductal, Breast 4Recurrence 3Pancreatic Neoplasms 3Neoplastic Cells, Circulating 3Multiple Myeloma 3Meningeal Neoplasms 3HER2-positive Gastric Cancer 3

Interventions

toripalimab 2Oxaliplatin 2tesetaxel 1indusatumab 1Trastuzumab 1S 1 (combination) 1Nivolumab 1Leucovorin 1Ipilimumab 1GC1118 1Fluorouracil 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma of the Stomach × Trastuzumab × Clear all
NCT05715931 2024-09-19

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Adenocarcinoma of the Stomach

Data powered by HemOnc (CC BY 4.0) Colophon âš¡